

Extension Seminar in Clinical Trials

Preliminary program

Self-paced learning package: available from Friday 22 March 2024

Presentation	Learning objectives	Presenter
Clinical trials manufacturing: considerations for TGA GMP licenced vs. non-licenced facilities and international perspectives on clinical trials manufacturing	 Compare the standards for GMP licenced manufacturing vs non-GMP licenced manufacturing Justify when you need a GMP licence to manufacture clinical trials Discuss GMP training essentials Identify the special considerations for advanced therapeutics Explore and apply data from international databases Explain the process and importance of being prepared for a GMP audit Explain the variables in international regulations and what is and is not appropriate in Australia 	Kerry Watts, Senior Project and Policy Officer, Advanced Therapeutics, Office for Health and Medical Research, NSW Ministry of Health, NSW Katrina Orr, Senior Teletrial Pharmacist, Australian Teletrial Program - Western Australia, WA Country Health Service, Department of Research and Innovation, WA
National Clinical Trials Framework	 Explain what the National Clinical Trials Governance Framework is and how it applies to health service organisations Discuss the history of the Clinical Trials Governance framework Describe how the clinical trials governance framework applies to pharmacy Identify the key areas of focus when coming up for accreditation 	Liam King, National Research Lead and Cancer Care Coordinator – Pharmacy, Ramsay Health, Brisbane, Qld
Human Research Ethics Committee (HREC) membership: how to review a submitted protocol and IB	 Overview information and essential documents provided in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) Describe the purpose and expected content of an Investigator's Brochure (IB) Outline requirements for a clinical trial protocol Explain key considerations, critical elements and best practices to facilitate a thorough and effective HREC review process for protocols and IBs 	June Challen, Specialist Pharmacist Investigational Drugs, SA Health, Adelaide, SA



Live seminar: Saturday 4 May 2024

All times listed are in AEST

Time (AEST)	Session	
0945-1000	Online login and registration available	
1000-1005	Welcome and introductions	
1005-1015	Review and open Q&A Liam King, National Research Lead and Cancer Care Coordinator – Pharmacy, Ramsay Health, Brisbane, Qld	
1015-1130	Growing your clinical trials unit Romana Cecchele, Senior Pharmacist – Investigational Drug Unit, Royal Prince Alfred Hospital, Sydney, NSW	
1130-1150	Break	
1150-1250	Budgeting and invoicing Eugenia Hong, Clinical Trials Pharmacy Manager, Pharmacy Department, Royal Melbourne Hospital, Melbourne, Vic	
1250-1330	Electronic pharmacy files and online accountability Janet Gaon, Senior Clinical Trials and Application Specialist Pharmacist, Chris O'Brien Lifehouse, Sydney, NSW	
1330-1345	Break	
1345-1445	Clinical trials and Good Manufacturing Practice Kerry Watts, Senior Project and Policy Officer, Advanced Therapeutics, Office for Health and Medical Research, NSW Ministry of Health, NSW Katrina Orr, Senior Teletrial Pharmacist, Australian Teletrial Program - Western Australia, WA Country Health Service, Department of Research and Innovation, WA	
1445-1500	Therapeutic Goods Administration (TGA) Good Clinical Practice (GCP) Inspection Program Anastasia Makshakova, Senior Good Clinical Practice (GCP) Inspector – Risk Management Section, Therapeutic Goods Administration, Australian Government Department of Health and Aged Care, Canberra, ACT	
1500-1515	National Clinical Trial Reform Agenda Dr Bernadette Aliprandi-Costa, Director Clinical Trials Policy Section, Health Economics and Research Division, Department of Health and Aged Care, Australian Government	
	Questions and discussion	
1515-1545	Questions and discussion	

Please note: presentation recordings from the live virtual seminar will not be available